Top 100 biotech ven­ture in­vestors; Bris­tol My­ers’ IL-12 breakup; Sci­en­tif­ic twist of fate; Track­ing bio­phar­ma lay­offs; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Thanks for read­ing. This week is ex­tra spe­cial — and not just be­cause of the Su­per Bowl — as it marks the 100th edi­tion of the End­points Week­ly. I’d love to hear from you on what you like about this re­port — and what you think could be bet­ter. You can al­ways re­ply to this email to get in touch. (Cor­rec­tion note: In last week’s email, I mis­tak­en­ly wrote that Bris­tol My­ers Squibb aban­doned two “pep­tide-masked” CT­LA-4 pro­grams. On­ly one of the two dis­con­tin­ued CT­LA-4 pro­grams was pep­tide-masked.)

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.